证券代码：300485 证券简称：赛升药业 公告编码：2024-039 北京赛升药业股份有限公司 2023 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 北京赛升药业股份有限公司（以下简称"公司"）2023 年年度权益分派方 案已获 2023 年 4 月 30 日召开的 2023 年年度股东大会审议通过，现将权益分派 事宜公告如下： 一、股东大会审议通过权益分配方案情况 1、公司于 2024 年 4 月 30 日召开 2023 年年度股东大会，审议通过了《2023 年度利润分配预案》，2023 年年度权益分配方案为：公司以 481,666,400 股为 基数，向全体股东每 10 股派发现金股利人民币 0.22 元（含税），共计分配股利 10,596,660.80 元（含税）。公司股本若因股权激励授予行权、新增股份上市、 股份回购等事项导致公司总股本扣减回购专户中的股份数而发生变化的，将按照 分配总额不变的原则对分配比例进行调整。剩余未分配利润结转以后年度分配。 2、自上述权益分配方案披露至实施期间，公司股本总额未发生变化。 3、本次实 ...

证券代码：300485 证券简称：赛升药业 公告编号:2024-037 北京赛升药业股份有限公司 关于对外投资暨关联交易的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、对外投资概述 (一）对外投资基本情况 近日，北京赛升药业股份有限公司（以下简称"公司"或"乙方"）与宁 波美诺华锐合股权投资合伙企业（有限合伙）（以下简称"转让方"）、苏州 易合医药有限公司（以下简称"易合医药"、"目标公司"或"甲方"）签署 了《股权转让协议》（协议一）。公司以人民币 1,000 万元受让持有易合医药 5.6664%的股权，对应注册资本为 21.1029 万元。同时，公司与易合医药签署 了《战略合作协议书》（协议二），在多肽药物筛选、创新吸入递送技术等领 域达成合作共识。 （二）董事会审议投资议案的表决情况 公司于 2024 年 4 月 24 日召开的第五届董事会第三次会议、第五届监事会 第三次会议审议通过了《关于公司对外投资暨关联交易的议案》。董事会与会 董事以 5 票同意、0 票反对、0 票弃权，表决通过，关联董事马骉、马丽、王 雪峰回避表决。 根据《股票上市规则》 ...

Financial Performance - The company's revenue for Q1 2024 was ¥109,535,330.56, a decrease of 17.46% compared to ¥132,698,154.36 in the same period last year[4] - The net loss attributable to shareholders was ¥190,617,604.88, representing a significant decline of 23,235.01% from a profit of ¥823,935.60 in the previous year[4] - The net profit after deducting non-recurring gains and losses was ¥15,157,836.06, an increase of 383.81% compared to ¥3,132,988.59 in the same period last year[4] - The total profit for Q1 2024 was -¥225,040,253.45, a decrease of 9,329.95% from a profit of ¥2,438,151.69 in the same period last year[7] - The net profit for the period was -$192.35 million, a decrease of 47,421.38% compared to the previous period's profit of $0.41 million, primarily due to a decrease in fair value changes and investment income from associates[9] - The total comprehensive income amounted to -$192.28 million, reflecting a significant decline of 331,112.04% from the previous total of -$58,054.72, mainly attributed to reduced fair value changes and investment income[9] - The net profit attributable to the parent company was -190,617,604.88 CNY, compared to 823,935.60 CNY in the previous period, indicating a significant decline[23] - The total comprehensive income attributable to the parent company was -190,555,908.62 CNY, compared to 359,413.61 CNY in the previous period[23] Cash Flow - The net cash flow from operating activities was ¥42,114,786.47, a substantial increase of 783.06% from ¥4,769,162.32 in the previous year[4] - Cash received from operating activities decreased by 37.72% to $1.36 million compared to $2.19 million in the previous period, mainly due to reduced inter-company transactions[10] - The total operating cash inflow was 114,104,143.09 CNY, compared to 153,241,637.71 CNY in the previous period, reflecting a decrease[26] - The total operating cash outflow was 71,989,356.62 CNY, down from 148,472,475.39 CNY in the previous period[26] - The cash and cash equivalents at the end of the period were $126.24 million, a decrease of 38.48% from $205.20 million in the previous period, primarily due to increased investment in financial assets[11] - The cash and cash equivalents at the end of the period were 126,240,055.05 CNY, down from 205,198,355.58 CNY at the end of the previous period[27] Assets and Liabilities - Total assets at the end of Q1 2024 were ¥3,410,249,504.62, down 5.85% from ¥3,622,201,677.70 at the end of the previous year[4] - The company's total assets decreased to CNY 3,410,249,504.62 from CNY 3,622,201,677.70, a decline of 5.8%[20] - Current assets increased to CNY 1,401,590,451.04 from CNY 1,353,066,844.20, an increase of 3.5%[18] - Non-current assets decreased to CNY 2,008,659,053.58 from CNY 2,269,134,833.50, a decline of 11.5%[19] - The total liabilities decreased to CNY 134,942,399.57 from CNY 154,610,347.67, a reduction of 12.7%[20] - The equity attributable to shareholders decreased to CNY 3,245,458,776.88 from CNY 3,436,014,685.50, a decline of 5.5%[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 31,337, with no preferred shareholders[13] - The largest shareholder, Ma Xie, holds 49.51% of the shares, amounting to 238.46 million shares, indicating significant ownership concentration[13] Expenses - Research and development expenses decreased by 65.80% to ¥9,168,151.11 from ¥26,803,792.38 in the same period last year[7] - Total operating costs amounted to CNY 103,930,716.38, down from CNY 130,399,239.51, reflecting a reduction of 20.2%[21] Investment Income - The company reported a significant drop in investment income, with a loss of ¥82,973,397.25 compared to a gain of ¥674,100.99 in the previous year, a decline of 12,408.75%[7] - The total cash inflow from investment activities was 164,833,714.82 CNY, down from 440,315,257.64 CNY in the previous period[26] - The net cash flow from investment activities was -36,081,201.81 CNY, worsening from -25,465,487.62 CNY in the previous period[26] - The company reported a 252.40% increase in cash received from investment income, amounting to $13.43 million compared to $3.81 million in the previous period, indicating improved financial management[10]

证券代码：300485 证券简称：赛升药业 公告编号：2024-034 北京赛升药业股份有限公司 第五届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、会议召开情况 北京赛升药业股份有限公司（以下简称"公司"）第五届董事会第三次会议 于2024年4月24日在公司会议室召开，本次会议于2024年4月19日以通讯的方式向 所有董事送达了会议通知。会议应参会董事8人，实际参会董事8人，会议由董事 长马骉先生主持，公司监事、高级管理人员列席了本次会议。本次会议的召开符 合《中华人民共和国公司法》等有关法律、行政法规、部门规章、规范性文件和 《公司章程》的规定，会议决议合法、有效。 二、会议审议情况 经全体董事认真审议并表决，会议通过了以下议案： 1、审议通过《关于公司对外投资暨关联交易的议案》。 公司拟与宁波美诺华锐合股权投资合伙企业(有限合伙)、苏州易合医药有限 公司签署《股权转让协议》，公司以人民币1,000万元受让持有易合医药5.6664% 的股权，对应注册资本为21.1029万元。具体内容详见同日在巨潮资讯网披露的 《关于对外投资 ...

北京赛升药业股份有限公司 第五届监事会第三次会议决议 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、会议召开情况 北京赛升药业股份有限公司（以下简称"公司"）第五届监事会第三次会议 于 2024 年 4 月 24 日在公司会议室召开，本次会议于 2024 年 4 月 19 日以通讯的 方式向所有监事送达了会议通知。会议应参会监事 3 人，实际参会监事 3 人，会 议由监事会主席赵丽娜女士主持。本次会议的召开符合《中华人民共和国公司法》 等有关法律、行政法规、部门规章、规范性文件和《公司章程》的规定，会议决 议合法、有效。 证券代码：300485 证券简称：赛升药业 公告编号：2024-035 表决结果：赞成 3 票、反对 0 票、弃权 0 票、回避 0 票。 2、审议通过《关于公司〈2024年第一季度报告〉的议案》 公司监事会对公司《2024 年第一季度报告》进行了认真严格的审核，并发 表如下审核意见：经审核，监事会认为公司《2024 年第一季度报告》的编制和 审核程序符合法律、法规和《公司章程》的规定，报告内容真实、准确、完整地 反映了公司的实际情况， ...

北京赛升药业股份有限公司 关于召开2023年年度股东大会通知的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 北京赛升药业股份有限公司（以下简称"公司"）于 2024 年 4 月 8 日召开 的第五届董事会第二次会议审议通过了《关于提请召开公司 2023 年年度股东大 会的议案》，决议于 2024 年 4 月 30 日（星期二）召开 2023 年年度股东大会（以 下简称"会议"），现将会议的有关情况通知如下： 一、会议召开的基本情况 证券代码：300485 证券简称：赛升药业 公告编号：2024-032 1、会议届次：2023 年年度股东大会 2、会议召集人：公司董事会 3、会议召开的合法、合规性：本次股东大会会议召开符合有关法律、行政 法规、部门规章、规范性文件和公司章程的要求。 4、会议时间： 现场会议时间：2024 年 4 月 30 日 14 点 30 分 网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间为 2024 年 4 月 30 日 9：15-9：25、9：30-11：30 和 13：00-15：00；通过互联网 投票系统投票的 ...

Financial Performance - The company's operating revenue for 2023 was ¥476,569,581.71, a decrease of 35.12% compared to ¥734,546,852.59 in 2022[30]. - The net profit attributable to shareholders for 2023 was ¥102,917,838.16, down 49.73% from ¥204,734,954.33 in the previous year[30]. - The cash flow from operating activities for 2023 was ¥21,210,975.01, representing an 80.79% decline from ¥110,434,543.55 in 2022[30]. - Basic earnings per share for 2023 were ¥0.21, a decrease of 51.16% compared to ¥0.43 in 2022[30]. - The company reported a significant drop in net profit after deducting non-recurring gains and losses, with a loss of ¥42,093,070.95 in 2023 compared to a profit of ¥330,385.83 in 2022[30]. - The quarterly revenue for Q4 2023 was ¥82,745,891.36, showing a decline compared to previous quarters[32]. - The company reported a net profit of 2,537.73 million yuan for 2023, a decrease from 6,649.89 million yuan in 2022[37]. - Non-recurring gains and losses amounted to 145.01 million yuan in 2023, down from 204.40 million yuan in 2022, reflecting a decrease of approximately 29%[38]. Market and Product Strategy - The company plans to enhance its marketing efforts, expand its sales team, and seek opportunities in provincial platform bidding and volume-based procurement[4]. - The company is focusing on strengthening product research and technological innovation, particularly in restoring production and sales of clinically short-supplied products[5]. - The company plans to focus on new product development and market expansion strategies in the upcoming year[30]. - The company is actively involved in the development of new drugs and technologies, contributing to the overall growth of the pharmaceutical sector[42]. - The company is expanding its market presence through the development of new formulations and generics, including those for type 2 diabetes and ischemic stroke[76]. - The company aims to expand its market presence through strategic collaborations and resource integration[66]. - The company is actively seeking appropriate acquisitions in the pharmaceutical industry to expand its scale and strength, aiming for low-cost expansion[137]. Research and Development - The company is continuously enhancing its R&D capabilities and optimizing project selection to ensure alignment with market needs and clinical acceptance[10]. - The company has invested in R&D and collaborations with academic institutions to accelerate product development and maintain technological advantages[53]. - The company has established an antibody drug discovery platform, which will provide external services and enhance its product line[90]. - The R&D department has filed for 36 new patents, with 22 already granted, reflecting the company's commitment to innovation[168]. - The company is actively developing antibody drugs for tumor and immune-related diseases, with initial research on promising candidates underway[76]. - The company is conducting preclinical research on new cardiovascular drugs aimed at improving microcirculation, with ongoing pharmacological and toxicological studies[74]. Financial Management and Governance - The company has a complete and independent financial management system, with dedicated accounting personnel and independent decision-making capabilities[151]. - The company has a clear governance structure, including independent boards and committees, adhering to legal and regulatory requirements[151]. - The company has committed to enhancing investor relations management to improve information transparency and protect shareholder rights[147]. - The company has established a training program focusing on enhancing management capabilities, with quarterly offline empowerment activities planned for 2024[190]. - The company has a robust performance evaluation and incentive mechanism for senior management, ensuring transparency and compliance with legal regulations[148]. Challenges and Risks - The company faces risks from policy changes in the highly regulated pharmaceutical industry, which could impact market access and operational compliance[6]. - The company has faced uncertainty regarding its ability to continue as a going concern, as indicated in the audit report[30]. - The marketing network covers major cities in China, but the company anticipates challenges in market expansion due to changing demand and increased competition[7]. - The company is actively managing investment risks to protect shareholder interests and improve cash flow[125]. Production and Quality Control - The company has established a comprehensive production and sales system, ensuring quality control throughout the manufacturing process[48]. - The company is committed to improving product quality and has a systematic quality control system in place to mitigate risks associated with product quality[9]. - The company focuses on three main product series: cardiovascular, immune regulation (anti-tumor), and neurological medications[58]. - The company has a strong emphasis on safety, with no production accidents reported during the reporting period[59]. Shareholder Relations and Profit Distribution - The company reported a profit distribution plan, proposing a cash dividend of 0.22 yuan per 10 shares, based on a total of 481,666,400 shares[12]. - The total cash dividend for the reporting period accounted for 100% of the total distributable profit of 1,940,655,183.12 CNY[193]. - The company has held two shareholder meetings during the reporting period, reviewing 12 proposals to ensure shareholder rights[142]. Future Outlook - The company provided a positive outlook for 2024, projecting a revenue growth of 18% and aiming to reach 1.42 billion RMB[163]. - The company plans to enhance market development and promotion of existing and approved products, aiming for sustained innovation capabilities[128]. - The company aims to leverage mergers, collaborations, and strategic alliances to enhance its core competitiveness in the healthcare sector[128].

北京赛升药业股份有限公司 董事会审计委员会对会计师事务所2023年度履职情况评估 及履行监督职责情况的报告 根据《中华人民共和国公司法》《企业内部控制基本规范》《上市公司自律 监管指引第 2 号——创业板上市公司规范运作》和《国有企业、上市公司选聘会 计师事务所管理办法》等法律、法规和规范性文件的要求，北京赛升药业股份有 限公司（以下简称"公司"）董事会审计委员会本着勤勉尽责的原则，恪尽职守、 认真履职，对 2023 年度年审会计师事务所履职情况进行评估和监督。现将相关 情况报告如下： 会第二十三次会议审议通过了《关于续聘致同会计师事务所（特殊普通合伙）为 公司 2023 年度审计机构的议案》，公司独立董事对上述议案发表了事前认可意 见及同意的独立意见，该议案于 2023 年 4 月 20 日经 2022 年年度股东大会审议 通过。 二、2023 年年审会计师事务所履职情况 致同所为公司聘请的 2023 年度的审计机构，按照《审计业务约定书》，遵 循《中国注册会计师审计准则》和其他执业规范，结合公司 2023 年年报工作安 排，致同所对公司 2023 年度财务报告进行了审计，同时对公司募集资金存放与 实际使用 ...

信达证券股份有限公司 关于北京赛升药业股份有限公司 2023年度募集资金存放和使用情况的核查意见 信达证券股份有限公司（以下简称"信达证券"）作为北京赛升药业股份有限 公司（以下简称"赛升药业"或"公司"）的保荐机构，根据《深圳证券交易所创 业板股票上市规则》（2023年修订）《上市公司监管指引第2号——上市公司募集资 金管理和使用的监管要求》（2022年修订）和《深圳证券交易所上市公司自律监管 指引第2号-创业板上市公司规范运作》（2023年12月修订）等有关规定，对赛升药 业2023年度募集资金存放和使用情况进行了核查，核查情况及保荐意见如下： 一、募集资金基本情况 （一）首次公开发行募集资金情况 赛升药业首次公开发行股票并在创业板上市经中国证券监督管理委员会证监 许可[2015]1176号文核准并经深圳证券交易所同意，由主承销商信达证券通过深圳证 券交易所系统于2015年6月17日采用网下向询价对象询价配售与网上资金申购定价 发行相结合的方式，向社会公众公开发行了普通股（A股）股票3,000万股，发行价 为每股人民币38.46元，共募集资金115,380万元，扣除发行费用7,285.53万元后，募 集资 ...

关于北京赛升药业股份有限公司 2023 年度募集资金存放与使用情况 鉴证报告 致同会计师事务所（特殊普通合伙） 目 录 关于北京赛升药业股份有限公司 2023 年度募集资金 存放与使用情况鉴证报告 北京赛升药业股份有限公司 2023 年度募集资金 存放与实际使用情况的专项报告 1-3 致同会计师事务所（特殊普通合伙） 中国北京 朝阳区建国门外大街 22 号 赛特广场 5 层 邮编 100004 电话 +86 10 8566 5588 传真 +86 10 8566 5120 www.grantthornton.cn 关于北京赛升药业股份有限公司 2023 年度募集资金存放与实际使用情况 鉴证报告 致同专字（2024）第 110A005519 号 北京赛升药业股份有限公司全体股东： 我们接受委托，对后附的北京赛升药业股份有限公司（以下简称 赛升药业公 司）《2023 年度募集资金存放与实际使用情况的专项报告》（以下简称 "专项 报告"）执行了合理保证的鉴证业务。 按照《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求（2022 年修订）》和《深圳证券交易所上市公司自律监管指引第 2 号——创业 ...